Search

Your search keyword '"Perucca, E"' showing total 38 results
Start Over Author "Perucca, E" Publisher elsevier bv
38 results on '"Perucca, E"'

2. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy

Author

Malerba A., Ciampa C., De Fazio S., Fattore C., Frassine B., La Neve A., Pellacani S., Specchio L. M., Tiberti A., Perucca E., LICCHETTA, LAURA, TINUPER, PAOLO, Malerba A., Ciampa C., De Fazio S., Fattore C., Frassine B., La Neve A., Pellacani S., Specchio L.M., Tiberti A., Tinuper P., and Perucca E.

Subjects
Adult, Male, Topiramate, medicine.medical_specialty, Pediatrics, Adolescent, medicine.medical_treatment, Population, Lamotrigine, Young Adult, Epilepsy, medicine, Humans, antiepileptic drugs, Child, Psychiatry, education, Referral and Consultation, Aged, Aged, 80 and over, education.field_of_study, business.industry, Infant, Carbamazepine, Middle Aged, medicine.disease, Prescriptions, Anticonvulsant, Italy, Neurology, Child, Preschool, Epilepsy syndromes, Anticonvulsants, Drug Therapy, Combination, Female, Neurology (clinical), Levetiracetam, business, medicine.drug
Abstract

Summary Purpose To evaluate the pattern of prescription of antiepileptic drugs (AEDs) and other medications in a representative population of patients with refractory epilepsy attending tertiary referral centres in Italy. Methods Descriptive analysis of data obtained at baseline from 933 adults and 191 children with refractory epilepsy enrolled consecutively in an observational study at 11 tertiary referral centres in Italy. Multivariate logistic regression analysis was used to assess predictors of utilization of the most commonly prescribed AEDs. Results Polytherapy was used in 79% of adults and 75% of children, with over one-third of adults and children being prescribed ≥3 AEDs. In adults, the most commonly used AEDs were levetiracetam (35%), carbamazepine (34%) and lamotrigine (30%). In children, valproic acid was by far the most commonly used AED (46%), followed by carbamazepine (27%), topiramate (21%), and phenobarbital (20%). The most common AED in partial epilepsy was carbamazepine (331 out of 893 patients, 37%), followed by levetiracetam (33%) and lamotrigine (26%). In generalized or undetermined epilepsies, the AEDs most commonly used were valproic acid (139 out of 223 patients, 62%), lamotrigine (33%) and levetiracetam (28%). Second generation AEDs were prescribed in 81% of adults and 54% of children. Comedications used for indications other than epilepsy were used by 32% of adults and 17% of children. Conclusions Prescription patterns were consistent with current evidence about the spectrum of efficacy of individual AEDs in different epilepsy syndromes. The high prevalence of polytherapy, including combinations of three or more AEDs, is a cause for concern.

Published
2010
Full Text
View/download PDF

22. CYP2D6-related oxidation polymorphism in Italy

Author

Spina, E., primary, Campo, G.M., additional, Avenoso, A., additional, Caputi, A.P., additional, Zuccaro, P., additional, Pacifici, R., additional, Gatti, G., additional, Strada, G., additional, Bartoli, A., additional, and Perucca, E., additional

Published
1994
Full Text
View/download PDF

38. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (Open Prospective Randomized Long-term Effectiveness) trial

Author

Gabriella Colicchio, Lorella Minotti, Emilio Perucca, Louis Wagner, Philippe Ryvlin, Paolo Tinuper, Pradheep Raman, Hermann Stefan, Dang Khoa Nguyen, Frank Gilliam, Nelia Zamponi, Umberto Aguglia, Paolo Benna, Paul Boon, Alfonso Iudice, Mark Sadler, Ryvlin, P., Gilliam, F.G., Nguyen, D.K., Colicchio, G., Iudice, A., Tinuper, P., Zamponi, N., Aguglia, U., Wagner, L., Minotti, L., Stefan, H., Boon, P., Sadler, M., Benna, P., Raman, P., and Perucca, E.

Subjects
Adult, Male, medicine.medical_specialty, animal structures, Adolescent, Vagus Nerve Stimulation, Health-related quality of life, medicine.medical_treatment, Drug Resistance, Young Adult, Behavioral Neuroscience, Epilepsy, Quality of life, Seizures, Internal medicine, Anticonvulsant, medicine, Clinical endpoint, Humans, Epilepsy, Health-related quality of life, QOLIE-89, Seizures, Vagus nerve stimulation, Adverse effect, Depression (differential diagnoses), Aged, Full-Length Original Research, business.industry, Repeated measures design, Middle Aged, medicine.disease, Seizure, Treatment Outcome, Tolerability, Neurology, Anesthesia, embryonic structures, Quality of Life, Anticonvulsants, Female, Epilepsies, Partial, Neurology (clinical), Analysis of variance, Erratum, QOLIE-89, business, Vagus nerve stimulation, Human
Abstract

To evaluate whether vagus nerve stimulation (VNS) as adjunct to best medical practice (VNS + BMP) is superior to BMP alone in improving long-term health-related quality of life (HRQoL).PuLsE (Open Prospective Randomized Long-term Effectiveness) was a prospective, randomized, parallel-group, open-label, and long-term effectiveness study (conducted at 28 sites in Europe and Canada). Adults with pharmacoresistant focal seizures (n = 112) received VNS + BMP or BMP (1:1 ratio). Medications and VNS parameters could be adjusted as clinically indicated for optimal seizure control while minimizing adverse effects. Primary endpoint was mean change from baseline HRQoL (using Quality of Life in Epilepsy Inventory-89 total score; QOLIE-89). Secondary endpoints included changes in seizure frequency, responder rate (≥50% decrease in seizure frequency), Centre for Epidemiologic Studies Depression scale (CES-D), Neurological Disorders Depression Inventory-Epilepsy scale (NDDI-E), Clinical Global Impression-Improvement scale (CGI-I), Adverse Event Profile (AEP), and antiepileptic drug (AED) load. The study was prematurely terminated due to recruitment difficulties prior to completing the planned enrollment of n = 362. Results for n = 96 who had baseline and at least one follow-up QOLIE-89 assessment (from months 3-12) were included in this analysis. Mixed model repeated measures (MMRM) analysis of variance was performed on change from baseline for the primary and secondary endpoints.Significant between-group differences in favor of VNS + BMP were observed regarding improvement in HRQoL, seizure frequency, and CGI-I score (respective p-values0.05, 0.03, and 0.01). More patients in the VNS + BMP group (43%) reported adverse events (AEs) versus BMP group (21%) (p = 0.01), a difference reflecting primarily mostly transient AEs related to VNS implantation or stimulation. No significant difference between treatment groups was observed for changes in CES-D, NDDI-E, AEP, and AED load.VNS therapy as a treatment adjunct to BMP in patients with pharmacoresistant focal seizures was associated with a significant improvement in HRQoL compared with BMP alone. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results